- Conditions
- Long Term Follow up Dry Eye Disease
- Interventions
- OC-01 Low Dose, 0.12 mg/mL, OC-01 Mid Dose, 0.6 mg/mL, OC-01 High Dose, 1.2 mg/mL, Placebo (vehicle) nasal spray
- Drug
- Lead sponsor
- Oyster Point Pharma, Inc.
- Industry
- Eligibility
- 22 Years and older
- Enrollment
- 101 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2019
- U.S. locations
- 3
- States / cities
- Newport Beach, California • Indianapolis, Indiana • Andover, Massachusetts
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–2
of 2
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Dry Eye Disease
- Interventions
- OC-01 (varenicline) nasal spray, Placebo (vehicle) nasal spray
- Drug
- Lead sponsor
- Oyster Point Pharma, Inc.
- Industry
- Eligibility
- 22 Years and older
- Enrollment
- 182 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018
- U.S. locations
- 3
- States / cities
- Newport Beach, California • Indianapolis, Indiana • Andover, Massachusetts